Details

Autor(en) / Beteiligte

• Tenorio, Jair
• Mansilla, Alicia
• Valencia, María
• Martínez-Glez, Víctor
• Romanelli, Valeria
• Arias, Pedro
• Castrejón, Nerea
• Poletta, Fernando
• Guillén-Navarro, Encarna
• Gordo, Gema
• Mansilla, Elena
• García-Santiago, Fé
• González-Casado, Isabel
• Vallespín, Elena
• Palomares, María
• Mori, María A.
• Santos-Simarro, Fernando
• García-Miñaur, Sixto
• Fernández, Luis
• Mena, Rocío
• Benito-Sanz, Sara
• del Pozo, Ángela
• Silla, Juan Carlos
• Ibañez, Kristina
• López-Granados, Eduardo
• Martín-Trujillo, Alex
• Montaner, David
• Heath, Karen E.
• Campos-Barros, Ángel
• Dopazo, Joaquín
• Nevado, Julián
• Monk, David
• Ruiz-Pérez, Víctor L.
• Lapunzina, Pablo

Titel

A New Overgrowth Syndrome is due to Mutations in RNF125

Ist Teil von

• Human mutation, 2014-12, Vol.35 (12), p.1436-1441

Ort / Verlag

United States: Blackwell Publishing Ltd

Erscheinungsjahr

2014

Link zum Volltext

Quelle

Wiley Online Library - AutoHoldings Journals

Beschreibungen/Notizen

• ABSTRACT Overgrowth syndromes (OGS) are a group of disorders in which all parameters of growth and physical development are above the mean for age and sex. We evaluated a series of 270 families from the Spanish Overgrowth Syndrome Registry with no known OGS. We identified one de novo deletion and three missense mutations in RNF125 in six patients from four families with overgrowth, macrocephaly, intellectual disability, mild hydrocephaly, hypoglycemia, and inflammatory diseases resembling Sjögren syndrome. RNF125 encodes an E3 ubiquitin ligase and is a novel gene of OGS. Our studies of the RNF125 pathway point to upregulation of RIG‐I‐IPS1‐MDA5 and/or disruption of the PI3K‐AKT and interferon signaling pathways as the putative final effectors. We have identified four mutations in a novel overgrowth gene, RNF125 (Fig A), in six patients with overgrowth, macrocephaly, intellectual disability, mild hydrocephaly, hypoglycaemia and inflammatory diseases resembling Sjögren syndrome. RNF125 encodes an E3 ubiquitin ligase. Functional characterisation showed that the mutations resulted in a dysregulation of RNF125 mRNA expression (Fig B). Additionally, clear differences in induction and degradation kinetics of RIG‐I, a RNF125 target protein, between patients and control fibroblasts were observed (Fig C‐E).